Pure Biologics SA products

In cancer, a balance between immune system effector and regulatory cells becomes disturbed. Regulatory T cells inhibit the activity of effector cells, including NK cells, a process known as immunosuppression. The PB003 (PureActivator) project embraces a novel approach, aiming to develop a drug based on a bimodal fusion protein, which synergistically activates NK cells and minimizes immunosuppression in the lung cancer tumor microenvironment.

Triple-negative breast cancer (TNBC) is a highly proliferative, rapidly growing, and aggressive form of cancer. TNBC can be further categorized into three types: Type 1 (also known as the “cold” type) is characterized by a tumor with low infiltration of immune cells into the tumor microenvironment; Type 2 is characterized by inactive cells of the innate immune system; Type 3 (also known as the “hot” type) is characterized by an immune system response that remains undisturbed. The aim of the PB004 (PureBIKE) project is to develop bispecific antibodies that convert a ‘cold’ TNBC tumor into a ‘hot’ tumor, rendering it more visible to the immune system.

Colorectal cancer (CRC) is the second-most common cancer diagnosed in women and third-most in men. Based upon five-year survival rates, chances of becoming cured remain to be approximately 65%. Therapies targeting immunological checkpoints, or more specifically their inhibition, promise effective treatment options for patients with metastatic forms of this disease. In the PB001 project, Pure Biologics aims to develop a recombinant bispecific antibody as a therapeutic candidate for immunotherapy in colorectal cancer.

Neuromyelitis optica (NMO) is an neurological autoimmune condition classified as a rare disease. Because of this classification, NMO lacks effective treatment options, since it is not of primary interest to the pharmaceutical industry. However, considerable social and institutional support exists for developing new therapies for such rare diseases. The PB002 (AptaPheresis) project aims to develop a novel, aptamer-based therapeutic medical device, to be used during selective plasmapheresis in NMO patients who are experiencing the life-threatening symptoms of this disease.

Myasthenia gravis (MG) is an autoimmune condition classified as a rare disease. Accordingly, myasthenic patients lack effective treatment options, as this rare disease is not a primary interest of the pharmaceutical industry. However, considerable social and institutional support exists for the development of new therapies to treat rare diseases. The PB005 (AptaMG) project aims to develop a novel aptamer-based therapeutic medical device, to be used during an immunoadsorption procedure on patients experiencing myasthenic crisis, a life-threatening exacerbation of myasthenia symptoms.